GlassScriptPhysician profile
Roberta Ann Bianco
NPI 1356435846
$7,181.48
in general payments reported to CMS, 2019-2025
35 companies · $871 in 2025
The $871 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $1,156 · 2022: $818 · 2023: $1,621 · 2024: $1,855 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,267 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.60 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,009.37 | 2019-2020 | |
| Novo Nordisk INC | $765.44 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $688.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $578.45 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $455.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $384.93 | 2019-2025 | |
| Lilly USA, LLC | $351.31 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $338.22 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $273.69 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $271.40 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $258.49 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $241.93 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Janssen Pharmaceuticals, INC | $195.47 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $172.82 | 2019-2023 | |
| Globus Medical, INC. | $167.81 | 2025 | Senza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $108.45 | 2024-2025 | Inspire |
| Currax Pharmaceuticals LLC | $106.50 | 2023-2025 | Contrave, Nexlizet, Nexletol |
| Horizon Therapeutics Plc | $92.11 | 2019-2020 | |
| Lundbeck LLC | $88.05 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $78.56 | 2022-2025 | |
| Daiichi Sankyo INC. | $67.31 | 2019-2023 | Injectafer |
| Boston Scientific Corporation | $59.41 | 2023 | |
| Arbor Pharmaceuticals, INC. | $54.72 | 2019 | |
| Axsome Therapeutics, INC. | $52.68 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $48.80 | 2019-2022 | |
| Vivus LLC | $45.19 | 2024 | Qsymia |
| Otsuka America Pharmaceutical, INC. | $39.64 | 2023-2024 | Rexulti |
| Genentech USA, INC. | $36.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.21 | 2022-2024 | Livalo |
| Avvisto Therapeutics, LLC | $19.89 | 2024 | Cycloset |
| Philips North America LLC | $19.69 | 2024 | (Ck7) Extended Holter |
| Acella Pharmaceuticals, LLC | $19.24 | 2025 | NP Thyroid 60 |
| Eisai INC. | $17.42 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.